<p>
    Listing and Waitlist Management (SAH):
</p>
<p>
    Following is for patients experiencing their first episode of liver decompensation due to alcohol and who may not meet traditional 6-month abstinence requirements.
</p>
<p>
    <strong>Eligibility Criteria:</strong>
</p>
<ul>
    <li data-list-item-id="ea156ab24d06254321b6c2d09510b89af">
       Medical Inclusion Criteria:
        <ul>
            <li data-list-item-id="e44fb59ff29493cf0d87d5f6a1c3af950">
               First decompensating liver event &nbsp;
            </li>
            <li data-list-item-id="ed03d47b4df2c7b12daf431c34a704c1d">
               Maddrey’s Discriminant Function ≥32. &nbsp;
            </li>
            <li data-list-item-id="e67961ecba9026108aac6125443b1f800">
               Lille Model score ≥0.45 after 7 days of corticosteroids, increasing MELD score while on therapy, or contraindication to steroid therapy are all acceptable indicators.
            </li>
            <li data-list-item-id="ee9ae1bacf4af4becd5e32e3836411e68">
               Diagnosis must be confirmed by liver biopsy. &nbsp;
            </li>
            <li data-list-item-id="e5eeef136f2ec500402f22edc6784b045">
               No absolute contraindications to transplantation.
            </li>
        </ul>
    </li>
    <li data-list-item-id="e432e6b85d4ab03b9edc5c430e072cf7c">
       Psychosocial Inclusion Criteria:
        <ul>
            <li data-list-item-id="e04d8689e38aa53667cdbc2e2dbab945d">
               Willingness and capacity to abstain from alcohol
            </li>
            <li data-list-item-id="e35d01a409d723761921538cd3cb1fa04">
               Engage in addiction treatment pre- and post-transplant
            </li>
            <li data-list-item-id="e9e299b57e720e7d45b8197eaa58e7240">
               No more than one previously failed alcohol use disorder (AUD) treatment
            </li>
            <li data-list-item-id="ef4f55c4199a9189d042604e0fbf37ec4">
               They should not have any active substance use disorder (except cannabis or tobacco), or untreated, severe psychiatric illness that would interfere with treatment adherence. &nbsp;
            </li>
            <li data-list-item-id="ec178a833c505a3439a8928e947fd6fa0">
               Reliable contact, stable housing, and a dedicated support person are mandatory.&nbsp;
            </li>
        </ul>
    </li>
</ul>    
<strong>Evaluation Process: </strong>
    <table class="table table-bordered">
        <tbody>
            <tr class="table-secondary">
                <td>
                    Stage&nbsp;
                </td>
                <td>
                    Tasks&nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    <p>
                        Referral Phase &nbsp;
                    </p>
                    <p>
                        (Days 1–11)&nbsp;
                    </p>
                </td>
                <td>
                    <ul>
                        <li data-list-item-id="e79da942a4732aadf0a49dfefdd2756b3">
                            Referring physicians assess clinical severity using Maddrey DF and initiate steroid therapy. &nbsp;
                        </li>
                        <li data-list-item-id="e1f8c1eaca857e6387c548bf64206bfa1">
                            At Day 7, the Lille Model score is calculated to evaluate response. &nbsp;
                        </li>
                        <li data-list-item-id="ec0ae7d5122314adcb633a603d061853d">
                            Patients meeting criteria are referred to the ALD program, and a liver biopsy is arranged. &nbsp;
                        </li>
                        <li data-list-item-id="ed8c3aa34bde48f91b7311ea766d13a62">
                            A completed referral form and psychosocial questionnaire must be submitted.&nbsp;
                        </li>
                    </ul>
                </td>
            </tr>
            <tr>
                <td>
                    <p>
                        Consultation Phase &nbsp;
                    </p>
                    <p>
                        (Days 12–14)&nbsp;
                    </p>
                </td>
                <td>
                    <ul>
                        <li data-list-item-id="e9f1c0a9ceffb8fc38acd5367a2efde31">
                            Addiction Psychiatry and Social Work teams assess the patient’s psychosocial suitability, including alcohol use testing with EtG. &nbsp;
                        </li>
                        <li data-list-item-id="ec43d2ef57f6b2d2a9c69d2227032d486">
                            Patients capable of consenting sign an agreement to remain abstinent &amp; engage in treatment. &nbsp;
                        </li>
                        <li data-list-item-id="e25b47335cb38ba256d58d58dec6f1b29">
                            If deemed eligible, a medical assessment follows. All findings are reviewed by the transplant listing committee, and a listing decision is made&nbsp;
                        </li>
                    </ul>
                </td>
            </tr>
            <tr>
                <td>
                    Waitlist Management&nbsp;
                </td>
                <td>
                    <ul>
                        <li data-list-item-id="e62d58d8a07f278cdbfbe0faf7e2f1a6c">
                            Patients accepted into the program will be monitored monthly for clinical stability and alcohol use, including Na MELD scoring, EtG or CDT testing, and monthly addiction and transplant team check-ins.
                        </li>
                        <li data-list-item-id="e2356dd650dfa1d153ac7eb85bf4d35e4">
                            Failure to adhere to medical/addiction follow-up may result in the patient being placed on hold or removed from the waitlist. &nbsp;
                        </li>
                        <li data-list-item-id="efaadf9c4607b2b969fb90ba1caeda882">
                            First positive alcohol test results in hold; a second leads to removal. &nbsp;
                        </li>
                        <li data-list-item-id="e85af1ab8aabb6ac06ab4858aea9d6a95">
                            Patients may also be removed for loss of follow-up, poor psychosocial support, or voluntary withdrawal from transplant consideration.&nbsp;
                        </li>
                    </ul>
                </td>
            </tr>
        </tbody>
    </table>

    <p>
    <strong>Post-Transplant Follow-Up:</strong> Patients will continue relapse prevention therapy and undergo random EtG or CDT testing in the first year post-transplant. Annual medical and psychosocial assessments will be conducted, with toolkits and support provided to community providers.
</p>
<p>
    <strong>Tools and Assessment Instruments:</strong>
</p>
<ul>
    <li data-list-item-id="e9f2476d163a406cc22e7813ffc8fc295">
        Biomarkers: EtG (urine), CDT (blood)
    </li>
    <li data-list-item-id="e1d8e1231886094aa13d2e215e8390fe2">
        Psychosocial Tools: SIPAT (Stanford Integrated Psychosocial Assessment for Transplant), HRAR (High Risk Alcohol Relapse), ARRA (Alcohol Relapse Risk Assessment)&nbsp;
    </li>
</ul>